BiotechTube
NuCana

NuCana

NCNA
Edinburgh, United Kingdom
nucana.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

NCNA · Stock Price

USD 2.09-6.31 (-75.12%)
Market Cap: $8.8M

Historical price data

Overview

NuCana's mission is to significantly improve survival outcomes for cancer patients by leveraging its proprietary ProTide technology platform to develop next-generation chemotherapy agents. The company has advanced multiple candidates into clinical development, with its lead programs, NUC-3373 and NUC-7738, demonstrating clinical activity and favorable safety profiles in mid-stage trials. NuCana's strategy involves applying its phosphoramidate chemistry to overcome the pharmacological limitations of established nucleoside analogs, thereby creating new standards of care. Despite promising science, the company faces significant financial and clinical execution risks as it seeks to advance its pipeline towards pivotal studies.

Oncology

Technology Platform

Proprietary ProTide phosphoramidate chemistry platform designed to transform established nucleoside analog chemotherapy drugs into novel prodrugs with enhanced intracellular activation, improved efficacy, and reduced toxicity.

Pipeline

7
7 drugs in pipeline1 in Phase 3
DrugIndicationStageWatch
NUC-1031 + Gemcitabine + CisplatinBiliary Tract CancerPhase 3
Fosifloxuridine Nafalbenamide + Leucovorin + Irinotecan + Be...Colorectal CancerPhase 2
NUC-1031 500 mg + NUC-1031 750mgOvarian CancerPhase 2
Fosifloxuridine Nafalbenamide + Leucovorin + Pembrolizumab +...Advanced CancerPhase 1/2
NUC-3373 + leucovorin + NUC-3373 + NUFOX + NUFOX + VEGF path...Colorectal CancerPhase 1/2

Funding History

4
Total raised:$182M
PIPE$25M
IPO$100M
Series B$37M
Series A$20M

Opportunities

NuCana's ProTide candidates target multi-billion dollar chemotherapy markets, including colorectal and biliary tract cancers, with the potential to displace generic incumbents by demonstrating superior efficacy or tolerability.
The NUC-7738 program addresses the growing need for therapies in checkpoint inhibitor-resistant cancers, a high-value niche with significant unmet medical need.

Risk Factors

The company faces extreme financial risk with a precarious cash position and low market valuation, threatening its ability to fund operations.
Clinical development risk remains high, as success requires demonstrating clear superiority over cheap, entrenched generic chemotherapies in rigorous late-stage trials.
Commercial adoption presents a further hurdle, requiring compelling data to drive a switch from established standards of care.

Competitive Landscape

NuCana competes directly with generic chemotherapy incumbents and other next-generation chemotherapy formulations. Its broader competitive set includes targeted therapies and immunotherapies that are shifting treatment paradigms earlier in disease. The company's differentiation hinges entirely on producing robust clinical data proving its ProTides offer a meaningful therapeutic advantage.

More companies in Small Molecule Drugs →More companies in United Kingdom →